Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial.
Saved in:
| Title: | Transient responses and significant toxicities of anti-CD30 CAR T cells for CD30+ lymphomas: results of a phase 1 trial. |
|---|---|
| Authors: | Brudno JN; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Natrakul DA; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Karrs J; Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Patel N; Hematology Section, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD., Maass-Moreno R; Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD., Ahlman MA; Department of Radiology and Imaging, Medical College of Georgia, Augusta, GA., Mikkilineni L; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Mann J; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Stroncek DF; Center for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD., Highfill SL; Center for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, MD., Fromm GC; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Patel R; Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Pittaluga S; Hematopathology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD., Kochenderfer JN; Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. |
| Source: | Blood advances [Blood Adv] 2024 Feb 13; Vol. 8 (3), pp. 802-814. |
| Publication Type: | Clinical Trial, Phase I; Journal Article |
| Journal Info: | Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
